NS-398, 0.2 mM nimesulide, and 50 mM acetaminophen, respectively (data not shown). About 3 to 10 times of the concentrations of NSAIDs, i.e. 1 mM indomethacin, 1 mM aspirin, 0.1 mM NS-398, 2.5 mM nimesulide, and 500 mM acetaminophen, respectively, were used. By using these concentrations of NSAIDs PGD 2 release was almost completely inhibited ( Fig. 1, shown later ), but these concentrations were not toxic to the cells from the morphological observations. The cells were pre-treated with each NSAID and 100 ng/ml LPS for 4 h, and then washed with 1 ml of F-12 complete medium once, and then the fresh complete medium was added. The cells were cultured for a further 4 h and the resulting medium was removed for PGD 2 measurement with an enzyme immunoassay kit for PGD 2 -methoxime (MOX) (Cayman Chemical Co., Ann Arbor, MI, U.S.A.). PGD 2 was assayed according to the manufacturer's instructions. Briefly, 50 ml of the culture medium was mixed with 50 ml of ice-cold acetone on ice. After 10 min, a supernatant was obtained by centrifugation at 15000 rpm for 2 min at 4°C. The lower phase was washed with 0.6 ml of ice-cold acetone, and then centrifuged as described above, and the resultant upper acetone phase was collected and combined with the former supernatant. The combined supernatant fraction was evaporated and methoximated. After appropriate dilution, the PGD 2 -MOX standard and methoximated samples were added to the wells of a mouse anti-rabbit IgG-coated 98-well-plate, and then PGD 2 -MOX-acetylcholinesterase conjugate and PGD 2 -MOX-antiserum were added, followed by incubation for 18 h at room temperature. Finally, Ellman's reagent was added, and the color was developed for 80 min and detected at 405 nm with a Multiscan plus microplate reader (Titertek Multiskan ® , Lab Systems, Finland).
Preparation of Cell Homogenates RAW 264.7 cells were cultured with or without NSAIDs after LPS-treatment as described above in 100-mm diameter plastic Petri dishes. After washing with 10 ml complete medium and then 5 ml of ice-cold PBS, the cells were scraped off with a cell scraper (Corning Coster Inc.) with 1 ml of ice-cold PBS. They were centrifuged at 7000 rpm for 20 s at 4°C (Tomy, model MRX-150), and then washed consequently with 1 ml of ice-cold PBS, 20 mM Tris-HCl, pH 7.5, containing 0.85% NaCl, and then 20 mM Tris-HCl, pH 7.5. The cell precipitates were suspended in 100 ml of ice-cold 20 mM Tris-HCl, pH 7.5, and then homogenized by sonication on ice 3 times for 3 s at 20 watts at 10 s intervals with a sonicator (Heat Systems Inc.).
Assay of PGHS Activity in the Presence or Absence of NSAIDs PGHS activity was assayed as described 8) with [ 14 C]AA as a substrate. The reaction mixture (100 ml), composed of 0.8 mM phenol in 80 mM Tris-HCl, pH 8.0, and 100 mg cell homogenate prepared as described above, was preincubated at 37°C for 1 min with or without a NSAID, followed by the addition of 17.2 mM [ 14 C]AA to start the reaction. After incubation at 37°C for 1 min, the reaction was terminated by the addition of 13 ml of ice-cold 0.5 N HCl. The reaction products were extracted with 1 ml ethylacetate and then analyzed by TLC with a solvent system of chloroform/ethyl acetate/methanol/acetic acid/water (70/30/8/1/0.5, v/v/v/v/v). 9) Each radio-labeled metabolite or AA was quantified with a BAS2000 bioimage analyzer (Fuji Photo Film, Tokyo). 3) The net amount of each product was calculated by multiplication of the [ 14 C]AA concentration in the reaction mixture by the ratio of each product to the total radioactive materials. Because PGH 2 was rapidly metabolized to PGA 2 , PGB 2 , PGD 2 , PGE 2 , PGF 2a , and HHT under these assay conditions, the amounts of these metabolites were summed and used as the PGHS activity value. The background value obtained without the enzyme in the reaction mixture was subtracted from the results. Under these conditions the enzyme activity was completely inhibited by 100 mM indomethacin. One unit of the enzyme activity was defined as that synthesized one pmol of PGs on incubation at 37°C during the reaction period.
Detection of PGHS-2 Protein The cell homogenate prepared as described above was subjected to SDS-polyacrylamide gel electrophoresis/Western blotting as described below. Each homogenate, equivalent of twenty micrograms of protein, was loaded onto a 4-20% (w/v) gradient gel (PAG Mini "DAIICHI"; Daiichi Pure Chemicals Co., Ltd., Tokyo) after treatment with SDS-sample buffer containing 5% b-mercaptoethanol, according to Laemmli. 10) After electrophoresis according to Fairbanks et al., 11) proteins were electro-transferred to a polyvinyldene fluoride (PVDF) membrane (Immobilon P ® ; Millipore, Bedford, MA, U.S.A.). The membrane was rinsed and blocked with milk casein (Snow Brand, Sapporo, Japan) for 30 min at 37°C. It was then incubated with a polyclonal anti-PGHS-2 antibody (Oxford, Oxford, MI, U.S.A.) for 2 h at 37°C. Finally, the immune complex on the PVDF membrane was detected using an enhanced chemiluminescence (ECL) system with horseradish peroxidase-conjugated second antibodies (New England Biolabs, Beverly, MA, U.S.A.). 8) Reverse-Transcription Polymerase Chain Reaction (RT-PCR) Analysis of PGHS-2 mRNA in NSAID-and/or LPS-Treated Cells RAW 264.7 cells (2.5ϫ10 6 cells/5 ml complete medium/60-mm-diameter dish) were cultured for 20 h and then washed twice with 2.5 ml of fresh complete medium. Then they were incubated at 37°C for 1 h in 5 ml of fresh complete medium with or without a NSAID in the presence or absence of 100 ng/ml LPS. Total RNA was isolated from the cells with a RNeasy mini TM kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Detection of PGHS-2 mRNA was performed by the RT-PCR method. First-strand cDNA was synthesized with a Retro Script TM first-strand synthesis kit for RT-PCR (Ambion ® , Austin, TX, U.S.A.) using oligo-d(T) 16 at 42°C for 60 min in a 20 ml reaction mixture containing 2 mg of total RNA. After denaturation at 92°C for 10 min followed by cooling at 4°C, the cDNA was used for amplification. For PCRs, 1 ml of denatured cDNA was amplified in a final volume of 25 ml of Super Taq Premix (Sawady Technology, Tokyo) containing 50 pM each primer. PCRs were performed in a Hybaid thermal cycler, PCR Sprint (Hybaid, Ashford, England). A program of 25 cycles of 93°C for 90 s, 65°C for 2 min, and 72°C for 2 min, with final 10 min extension at 72°C was used. The specific primers used included, for PGHS-2, 5Ј-CTTCCTGATTCAAAAGAAGTGCTGG-3Ј (forward) and 5Ј-ATGGTGGCTGTTTTGGTAGGCTGT-3Ј (reverse). The predicted size of the fragment is 1268 bp. 12) As a control for RNA extraction, b-actin, a housekeeping gene was used. The cDNA was subjected to 20 cycles of amplification at 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, using 5Ј-GATG-GTGGGTATGGGTCAGAAGGA-3Ј (forward) and 5Ј-GCT-CATTGCCGATAGTGATGACCT-3Ј (reverse) as the primers. The predicted size of the fragment is 630 bp. 13) The amplified products were subjected to electrophoresis with 1% agarose gel and visualized with ethidium bromide. 8) Other Assay Protein was determined according to Bradford. 14) 
RESULTS

Re-incubation of LPS-and NSAID-Treated Macrophages after Washing off the Additives
We have reported that RAW 264.7 macrophage cell line released AA shortly after the LPS-treatment, and it released PGs, mainly PGD 2 , after PGHS-2 induction. The released amount of AA itself was decreased to half of that of PGD 2 after incubation for 4 h. 3) To study the effect of NSAID-removal on the PGs release from macrophage cells after both LPS and NSAIDtreatment, we incubated cells with LPS in the presence or absence of NSAID for 4 h and then washed and re-incubated the cells for additional 4 h without the additives. Assaying the amount of PGD 2 released during the re-incubation was performed by enzyme immunoassay method as described under Materials and Methods. PGD 2 -release from RAW 264.7 macrophage cells was inhibited by all of the NSAIDs, i.e. indomethacin, aspirin, NS-398, nimesulide, and acetaminophen during primary incubation with LPS for 4 h as measured by the enzyme immunoassay method ( Fig. 1 ). However, this inhibition was completely reverted and more than twice of PGD 2 was released than that from the cells with LPS-but without NSAIDs-treatment, when none of the NSAIDs were included during the re-incubation ( Fig. 2a ). In addition to PGD 2 , AA was also released from cells into the medium, although the amount was half of that of PGD 2 during the re-incubation. Furthermore, the effect of primary treatment with both LPS and NSAID, e.g. 1 mM indomethacin, on AA release during the re-incubation for 4 h was not largely affected (less than 20%, data not shown). On the contrary, addition of NSAIDs to the re-incubation medium inhibited the PGD 2 -release ( Fig. 2b) . It is noteworthy that washing of LPS-treated cells after 4 h-incubation did not stop releasing PGD 2 (Fig. 2) .
The results suggest increase in PGHS activity and/or reactivation of PGHS enzyme after washing out NSAIDs. We next assayed PGHS activity by using [ 14 C]AA as a substrate as described under Materials and Methods. PGHS activity in the homogenate of the re-incubated cells was slightly increased by the pre-treatment of NSAIDs, although that of aspirin pre-treated cells showed exceptionally a slight decrease in the enzyme activity ( Fig. 3a) . These results suggest that addition of NSAIDs in the first incubation with LPS did not abolish PGHS activity from the cells completely but kept it mostly remained. On the other hand, in the homogenate of the re-incubated cells in the presence of indomethacin or aspirin, or NS-398, PGHS activity was inhibited strongly or slightly, respectively, while it was not inhibited in the samples treated with nimesulide or acetaminophen, (Fig. 3b ).
As an enhanced induction of PGHS-2 [4] [5] [6] and induction of PGHS-3 7) was reported, amount of PGHS-2 protein in the reincubated cells was examined by Western blotting method as described under Materials and Methods. The re-incubation increased the amount of PGHS-2 protein slightly in the cells without addition of NSAIDs (indomethacin, aspirin, and NS-398), or twice as much as that without NSAID-pre-treatment (nimesulide and acetaminophen) ( Fig. 4a ). On the other hand, addition of NSAIDs to the re-incubation medium again increased the PGHS-2 protein level more than four times compared to the control without NSAID-treatment ( Fig. 4b) .
These results suggest that the increase in PGHS-2 protein ( Fig. 4 ) and/or reactivation of PGHS enhanced the PGHS activity after removal of the NSAIDs and increased PGD 2 release.
Effects of NSAIDs on the Induction of PGHS-2 after LPS-Treatment Steroidal anti-inflammatory drugs are known to inhibit PGHS-2 induction by LPS-treatment, 2, 15) while NSAIDs are reported to enhance the induction. [4] [5] [6] In During the re-incubation, NSAIDs were either omitted (a) or added (b) throughout the experiments. The assay was performed as described in the legend to Fig. 1 . The results are shown as meansϮdeviation of duplicate measurements. The concentrations of NSAIDs used in this experiment were the same as in the legend to Fig. 1 . Abbreviations; EtOH, ethanol; Ind, indomethacin; Asp, aspirin; NS, NS-398; Nime, nimesulide; Acet, acetaminophen. addition to the experiment described above (Fig. 4) , we also studied the effects of various types of NSAIDs, i.e. indomethacin, aspirin, NS-398, nimesulide and acetaminophen, without washing and re-incubation. All of the NSAIDs studied here again enhanced the induction of PGHS-2 by LPStreatment both time-( Fig. 5 ) and dose-( Fig. 6 ) dependently, although none of them alone induced PGHS-2 without LPS (data not shown). On the other hand, 10 mM dexamethasone, a steroidal anti-inflammatory reagent, completely inhibited the induction of PGHS-2 protein after LPS-treatment. These results show the stimulatory effects of NSAIDs on the induction of PGHS-2 protein, suggesting both promotion of PGHS-2 synthesis and concomitant inhibition of PGHS-2 enzyme activity.
Effects of NSAIDs on Transcription of the PGHS-2 Gene after LPS-Treatment
To clarify the mechanism of the enhanced induction by NSAIDs, the effect of the NSAIDs on transcription of the PGHS-2 gene was studied on the cells treated with LPS and NSAIDs without washing and re-incubation. As reported previously, 8) PGHS-2 mRNA was expressed 1 h after LPS-treatment in RAW 264.7 cells, while none of the NSAIDs significantly promoted the expression of PGHS-2 mRNA after LPS-treatment ( Fig. 7) . These results show the little effect of NSAIDs on the PGHS-2 mRNA level, suggesting post-transcriptional elevation of PGHS-2 expression by NSAIDs.
Effect of NSAID-Treatment in the Presence of LPS on the Specific Activity of PGHS in Cell Homogenates
In addition to the re-incubation experiment shown in Fig. 3 , we further examined whether or not the PGHS activity had been abolished by the NSAIDs in the LPS-treated macrophages. We assayed the specific activity of PGHS in the homogenate of the cells treated for 4 h with both LPS and each NSAID. As described under Materials and Methods, the homogenate 
Fig. 5. Time-Dependent Induction of PGHS-2 after LPS-Treatment with or without NSAIDs
Cells were treated with both of each NSAID and 100 ng/ml LPS for various times, as described under Materials and Methods. PGHS-2 protein in the homogenate was detected by SDS-polyacrylamide gel electrophoresis/Western blotting as described under Materials and Methods followed by quantification as described in the legend to Fig. 4 . Ethanol (EtOH) was used as a vehicle solvent for NSAIDs. The concentrations of NSAIDs used in this experiment were the same as in the legend to Fig. 1. was prepared from cells washed after harvest but not re-incubated after washing. As shown in Fig. 8 , PGHS activity in the homogenates of both LPS and either indomethacin-, aspirin-or NS-398-treated cells decreased dependently on the NSAIDs (Figs. 8a-c) . On the other hand, the enzyme activity in the homogenate of nimesulide-treated cells increased dose dependently (Fig. 8d ). In the case of acetaminophen, PGHS activity only increased with the lower concentrations, i.e. not with higher doses (Fig. 8e) . These results show that some NSAIDs (indomethacin, aspirin and NS-398) inhibited the PGHS-2 activity in the LPS-treated macrophage cells, while others (nimesulide and acetaminophen) elevated it. It is suggested that the increased PGHS-2 proteins after treatment with the NSAIDs and LPS (Figs. 5, 6 ) exhibit their activity depending on the species of NSAID and the dose.
DISCUSSION
Washing and re-incubation of the cells treated with both LPS and NSAIDs resulted in increased PGD 2 -release ( Fig.  2a ), while addition of NSAIDs to the re-incubation medium inhibited PGD 2 release completely (Fig. 2b) , although induction of the PGHS-2 protein was strongly enhanced (Fig. 4b) .
When NSAIDs were not added in the re-incubation medium, the level of PGHS-2 in the homogenate became less than that of the cells in the presence of NSAIDs, the level being twice of the control at most (Fig. 4a ). As shown in Figs. 5 and 6, all NSAIDs used in this experiment enhanced PGHS-2 expression in the presence of LPS during the primary-incubation, both time and dose dependently. Re-incubation with these NSAIDs without re-addition of LPS also strongly enhanced PGHS-2 expression (Fig. 4b) . These results suggest that effects of LPS-treatment still continue after washing out LPS and may stimulate PGHS-2 expression successively. Although we cannot rule out a possibility of the involvement of peroxisome proliferator-activated receptor (PPAR) in this PGHS-2 expression, [4] [5] [6] other factors than PPAR may have an important role in the PGHS-2 expression during the re-incubation process because of short incubation period and LPS-treatment in this experiment. Besides, the addition of NSAIDs to the assay mixture with an LPS-treated macrophage homogenate inhibited PGHS activity (data not shown). These results suggest that NSAIDs inhibit PGHS activity if they are present in the cells or the assay mixture, and that NSAIDs induce higher levels of active PGHS-2 protein in the presence of LPS, which leads to elevated production of PGs after removal of NSAIDs.
Enhanced PGD 2 release through accelerated AA release is an attractive mechanism to explain the result. However, released free AA from cells during re-incubation was less than 5% of the total AA of the cells and the released PGD 2 was about 10% of that as calculated from the recovery of each radioactivity (data not shown). In addition, changes in AA release with NSAIDs were less than 20% of the control without NSAIDs. From these results we don't think this is feasible, although we cannot rule out this possibility of mechanism completely. Further experiments are required to find out how PGD 2 release is enhanced during the re-incubation after NSAIDs pre-treatment in the presence of LPS.
On the contrary, PGHS activity in the homogenate of the cells without re-addition of NSAIDs was slightly varied depending on the species of the NSAIDs, being either enhanced or decreased as compared to the control (Fig. 3a) . However, release of PGD 2 from these cells was increased independently to the species of the NSAIDs (Fig. 2a) , suggesting that the PGHS-2 activity in the homogenates does not explain the extents of the PGD 2 -release from NSAIDs-pretreated cells during re-incubation. This might be because we prepared the homogenate samples from 4-h-re-incubated cells, in which some of the PGHS-2 activity in the cells had been inactivated through self-inactivation mechanisms by its own reaction. 1) Another mechanisms underlying these discrepancies might be due to the differences in the rates and the extents of the removal of these NSAIDs from the cells, especially from the active sites of the PGHS-2 in these macrophages.
On the other hand, re-addition of indomethacin, aspirin, or NS-398 in the re-incubation inhibited PGHS activity (Fig.  3b ), suggesting decreased amount of active PGHS-2 in the resulting homogenate. In case of nimesulide or acetaminophen, PGHS activity was not inhibited by the pre-treatment of the reagent with or without re-addition in the re-incubation period. In these cases we think the reagents are removed during the preparation of the cell homogenates as described under Materials and Methods, and thus PGHS activity in the samples is restored.
Enhanced induction of PGHS-2 was common to the NSAIDs examined in this study. These NSAIDs apparently differ in the mode of action, i.e. selectivity to PGHS-2 and mechanism of inhibition. 1, 2) Ten mM Ibuprofen (class I; simple and competitive inhibitor) had a similar effect on the enhanced induction of PGHS-2 protein (data not shown) to that with indomethacin (class II; competitive, time-dependent, and reversible inhibitor) or aspirin (class III; competitive, time-dependent, and irreversible inhibitor). Both PGHS-2 selective (NS-398 and nimesulide) and non-selective (indomethacin and aspirin) NSAIDs also had a similar effect on the enhanced induction of PGHS-2. However, as PGHS activity in the cell homogenate from NSAID-treated and re-incubated cells varied depending on the species of NSAIDs, reversibility of the inhibition of PGHS with NSAIDs might be important in the reactivation of PGHS activity after withholding the use of some of the NSAIDs. There must be a common mechanism which enhance PGHS-2 induction by various NSAIDs after LPS-treatment. However, none of them significantly enhanced transcription of the PGHS-2 gene after LPS-treatment ( Fig. 7) , which might suggest important mechanisms underlying the post-transcriptional regulation of The assay was performed as described under Materials and Methods without further addition of NSAIDs. PGHS activity is shown relative to that in the homogenate of cells treated with LPS but without a NSAID, and are meansϮdeviation of duplicate measurements. The control value for PGHS activity was 105.8Ϯ15.2 (meanϮS.E.) units based on five independent measurements.
PGHS-2 induction.
On the other hand, NSAIDs themselves have been reported to induce [4] [5] [6] PGHS-2, although we could not detect PGHS-2 protein after NSAID-treatment in the absence of LPS in our experimental conditions. In addition, they have been reported to enhance [4] [5] [6] or suppress 5, 16) PGHS-2 expression at the transcriptional level, which was not observed in our experiment by assaying PGHS-2 mRNA in NSAID-treated cells. We also could not observe induction of PGHS-3, which was reported an inhibition by acetaminophen but resistant to the other NSAIDs. 7) These differences might be due to differences in cell type, culture conditions and/or concentrations of NSAIDs used, although we could not specify. In addition, it is noteworthy that Paik et al. reported inhibition of LPS-induced PGHS-2 expression by flufenamic acid at low serum concentration and longer incubation in RAW 264.7 cells. 5) Although we cannot compare our results directly with theirs because of differences in experimental conditions, some NSAIDs may inhibit LPS-induced PGHS-2 induction.
In this paper, we suggested enhanced induction of PGHS-2 protein by NSAIDs after LPS-treatment. However, we could not rule out the possibility of inhibition of PGHS-2 degradation by NSAIDs, as NSAIDs have been reported to inhibit tryptic digestion of PGHS-1. 17) Studies along these lines should be performed to examine this.
The effects of NSAIDs shown above seem to be important in relation to the adverse effect of NSAIDs, because these reagents enhanced PGHS-2 induction after LPS-treatment. In fact, we showed enhanced PGs release from macrophages after removal of the reagents following primary treatment of the cells with LPS and NSAIDs. Although further investigations on the NSAIDs used in the case of inflammation in animals and humans are needed, we must be careful about the time when we use NSAIDs and also when we stop using them.
